<description>&lt;div&gt; &lt;strong&gt;Show notes&lt;/strong&gt; &lt;br&gt;
To learn more about the FTC's most recent report on PBMs, &lt;a href="https://www.centerforbiosimilars.com/view/ftc-releases-second-report-on-pbms-meddling-in-generic-drug-markets"&gt;click here&lt;/a&gt;. &lt;br&gt;
To learn more about the FTC's first report on PBMs, &lt;a href="https://www.ajmc.com/view/ftc-finds-pbms-drive-up-drug-costs-squeeze-out-competitors"&gt;click here&lt;/a&gt;. &lt;br&gt;
To learn more about health care actions taken by the second Trump Administration during it's first month, &lt;a href="https://www.ajmc.com/view/5-key-health-care-moments-during-president-trump-s-first-month-back-in-office"&gt;click here&lt;/a&gt;. &lt;br&gt;
To learn more about the views of Mehmet Oz, MD (more commonly known as Dr. Oz) on price transparency ahead of his congressional confirmation hearings as President Trump's nominee for HHS Secretary, &lt;a href="https://www.thestreet.com/investing/dr-oz-reveals-how-to-fix-healthcare-in-america-14346120"&gt;click here&lt;/a&gt;. &lt;/div&gt;
</description>

In today’s episode, we dive into the FTC’s second interim report on PBMs, exposing key issues like preferential reimbursement for affiliated pharmacies. The findings raise questions about drug pricing transparency and PBM accountability.

Joining us is Joe Wisniewski, a PBM legislation and pricing expert from Turquoise Health, to discuss the report’s impact, biosimilars, and shifting regulations. We’ll also examine how a second Trump administration could reshape PBM practices and drug pricing.

Not So Different: A Podcast from The Center for Biosimilars

S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration?

S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration?

Description